J. B. CHEMICALS & PHARMACEUTICALS LIMITED

J. B. Chemicals & Pharmaceuticals Limited

JBCHEPHARM

INE572A01036

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:51 2024-05-23 EDT			5-day change	1st Jan Change
1,679 ^INR	-1.35%		-8.38%	+3.34%

05-22	Jefferies Adjusts JB Chemicals & Pharmaceuticals' Price Target to INR2,060 From INR2,000, Keeps at Buy	MT
05-21	Transcript : J. B. Chemicals & Pharmaceuticals Limited, Q4 2024 Earnings Call, May 21, 2024

J. B. Chemicals & Pharmaceuticals Limited Announces Demise of Managing Director, Shri Jyotindra B. Mody

July 21, 2020 at 11:37 pm

J. B. Chemicals & Pharmaceuticals Limited announced that Managing director Shri Jyotindra B. Mody, passed away last night.

Latest news about J. B. Chemicals & Pharmaceuticals Limited

Jefferies Adjusts JB Chemicals & Pharmaceuticals' Price Target to INR2,060 From INR2,000, Keeps at Buy	05-22	MT
Transcript : J. B. Chemicals & Pharmaceuticals Limited, Q4 2024 Earnings Call, May 21, 2024	05-21
J. B. Chemicals & Pharmaceuticals Limited Recommends Final Dividend for the Year 2023-2024	05-17	CI
J. B. Chemicals & Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-17	CI
J. B. Chemicals & Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-17	CI
KKR to buy India's Healthium Medtech at $839 million valuation, sources say	05-06	RE
J. B. Chemicals & Pharmaceuticals Limited Receives Order from Joint Commissioner State Tax, Lucknow II, Lucknow	04-26	CI
J. B. Chemicals & Pharmaceuticals Limited Appoints Akshay Tanna as A Non-Executive, Non-Independent Director	04-08	CI
J. B. Chemicals & Pharmaceuticals Limited Receives Order from Assessment Unit, Income Tax Department	03-22	CI
J. B. Chemicals & Pharmaceuticals Limited Announces Demise of Ranjit Shahani, Chairman and Non-Executive, Independent Director	03-09	CI
KKR Reportedly Considers Selling Controlling Stake in JB Pharma	02-28	CI
Jefferies Adjusts JB Chemicals & Pharmaceuticals' Price Target to INR2,000 From INR1,970, Keeps at Buy	02-08	MT
JB Chemicals' Consolidated Profit Climbs in Fiscal Q3; Shares Jump 4%	02-07	MT
J.B. Pharma Seeks Acquisitions	02-07	CI
Transcript : J. B. Chemicals & Pharmaceuticals Limited, Q3 2024 Earnings Call, Feb 07, 2024	02-07
J. B. Chemicals & Pharmaceuticals Appoints CFO	02-06	MT
JB Chemicals Names CFO	02-06	MT
Indian drugmaker J B Chemicals posts Q3 profit rise on strong demand	02-06	RE
J. B. Chemicals & Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-06	CI
J. B. Chemicals & Pharmaceuticals Limited Appoints Narayan Saraf as the Chief Financial Officer, with Effect from February 23, 2024	02-06	CI
J. B. Chemicals & Pharmaceuticals Limited Declares Interim Dividend for Financial Year 2023-24	02-06	CI
Transcript : J. B. Chemicals & Pharmaceuticals Limited - Shareholder/Analyst Call	12-22
J. B. Chemicals & Pharmaceuticals Limited Announces Execution of Trade Mark License Agreement with Novartis Innovative Therapies Ag and Promotion & Distribution Agreement with Novartis Healthcare Private Limited	12-19	CI
JB Pharma Seeks Acquisitions	11-24	CI
Jefferies Adjusts J.B. Chemicals & Pharmaceuticals' Price Target to INR1,680 From INR1,555, Keeps at Buy	11-09	MT

Chart J. B. Chemicals & Pharmaceuticals Limited

Duration

Period

Chart J. B. Chemicals & Pharmaceuticals Limited

More charts

J. B. Chemicals & Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredients (APIs). Its therapeutic categories include gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives and pharmacovigilance. The Company's lozenges products include center-filled, soft-centered lozenges; center-filled, powder lozenges; herbal lozenges, and medicated lozenges. The Company offers a complete range of contrast media products including X-ray, MRI, and ultrasound in India as well as internationally. The Company produces a wide range of dosage forms, such as tablets, capsules, liquids, IV infusions, ampoules, vials, ointments, cold rubs, lozenges and sips. Its brands include Rantac OD, RD, Ranraft, Metrogyl ER, Metrogyl O, Nicardia XL, Sporlac EVA and Sporlac G, among others.

Sector

Pharmaceuticals

Calendar

2024-08-07 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for J. B. Chemicals & Pharmaceuticals Limited

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1,679 INR

Average target price

1,911 INR

Spread / Average Target

+13.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
J. B. CHEMICALS & PHARMACEUTICALS LIMITED	+3.34%	3.17B
ELI LILLY AND COMPANY	+38.69%	723B
NOVO NORDISK A/S	+34.28%	595B
JOHNSON & JOHNSON	-4.49%	369B
MERCK & CO., INC.	+20.24%	332B
ABBVIE INC.	+2.12%	282B
ASTRAZENECA PLC	+17.02%	244B
NOVARTIS AG	+9.31%	208B
ROCHE HOLDING AG	-5.07%	205B
PFIZER, INC.	-0.35%	168B

Other Pharmaceuticals